Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:289-92.
doi: 10.2174/1874613601206010289. Epub 2012 Dec 14.

The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine

Valéria Ferreira  1 , Patrícia Moura, Sergio Crovella, Ricardo Sobhie Diaz, Adauto Castelo Filho, Ricardo Ximenes, Luiz Cláudio Arraes
Affiliations

The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine

Valéria Ferreira et al. Open AIDS J. 2012.

Abstract

In the present study, we investigated the influence of HIV-1 subtype in the response to the dendritic cell (DC) therapeutic vaccine for HIV. HIV-1 viral load and TCD8+/TCD4+ cell counts for up to 48 weeks after vaccination. Out of 19 immunized subjects, 13 were infected by subtype B, 5 by subtype F, and 1 by subtype D. Overall, 42.1% (8/19) achieved a viral load decline of ≥ 1 log(10) sustained up to 48 weeks after immunization. Such magnitude of viral load drop was seen in 80% (4/5) of subtype F infected patients, and in 23.0% (3/13) of the subtype B infected ones (p=0.08). Moreover, mean viral load decline was 1.32 log(10), for subtype F infected individuals compared to 0.5 log(10) among subtype B infected patients (p=0.01). The variation in TCD4+ cell count was not related to HIV-1 subtype. Larger studies are necessary to confirm the efficacy of this immunotherapy and the differential response according to the background genetic diversity of HIV-1.

Keywords: Dendritic cells; HIV-1 subtype; immunotherapy.; vaccine.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
T CD4+ Lymphocytes and viral load variation over time after dendritic cell vaccination among subtype B and subtype F infected individuals.
See this image and copyright information in PMC

References

    1. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003;101:4505–11. - PubMed
    1. Beuria P, Chen H, Timoney M, Sperber K. Impaired accessory cell function in a human dendritic cell line after human immunodeficiency virus infection. Clin Diagn Lab Immunol. 2005;12:453–64. - PMC - PubMed
    1. Salerno-Goncalves R, Lu W, Andrieu JM. Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease. J Virol. 2000;74:6648–51. - PMC - PubMed
    1. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359–65. - PubMed
    1. Soares MA, De Oliveira T, Brindeiro RM, et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS. 2003;17:11–21. - PubMed

LinkOut - more resources